Combined serine protease PRSS22 and CEA mRNA analysis identifies the majority of colon cancer patients that recur within 12 years.

Front Oncol · 2025 · PMC12406016 · PMID 40909962

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Both PRSS3 and PRSS22 showed a strong highly significant positive correlation with all seven biomarkers with r-values ranging from 0.2-0.5 for LNs of stage III and 0.5-0.9 for Stage IV patients indicating that these biomarkers are probably expressed by the same population of tumor cells.

also in 132,142 other papers

showed a trendno p-value reported

The median PRSS22 mRNA expression levels showed a trend of gradual increase across TNM stages: 0.003 (stage I), 0.006 (stage II), 0.005 (stage III), and 0.012 (stage IV) mRNA copies/18S rRNA unit.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.